Treatment for Community-Acquired Pneumonia
For previously healthy outpatients with community-acquired pneumonia, start with a macrolide (azithromycin, clarithromycin, or erythromycin) as monotherapy, but if comorbidities exist or recent antibiotic use within 90 days, use a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750mg) or a β-lactam plus macrolide combination. 1
Outpatient Treatment Algorithm
Previously Healthy Patients (No Comorbidities)
- First-line: Macrolide monotherapy (azithromycin, clarithromycin, or erythromycin) 1
- Alternative: Doxycycline (weaker evidence) 1
Patients with Comorbidities
Comorbidities include: chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancies, asplenia, immunosuppression, or antibiotic use within past 3 months 1
Choose ONE of:
- Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750mg) - strong recommendation 1
- β-lactam PLUS macrolide - strong recommendation 1
- Preferred β-lactam: High-dose amoxicillin (1g three times daily) or amoxicillin-clavulanate (2g twice daily)
- Alternatives: ceftriaxone, cefpodoxime, cefuroxime (500mg twice daily)
Critical caveat: In regions with high macrolide resistance (≥25% of S. pneumoniae with MIC ≥16 mg/mL), use the comorbidity regimen even for previously healthy patients 1
Inpatient Non-ICU Treatment
Two equally strong options:
- Respiratory fluoroquinolone monotherapy 1
- β-lactam PLUS macrolide combination 1
- Preferred β-lactams: cefotaxime, ceftriaxone, or ampicillin
- Ertapenem for selected patients with gram-negative risk factors (excluding Pseudomonas)
- Doxycycline acceptable alternative to macrolide
For penicillin allergy: Use respiratory fluoroquinolone 1
ICU/Severe CAP Treatment
Mandatory combination therapy with a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either azithromycin OR a fluoroquinolone 1
Special Situations in ICU:
Pseudomonas Risk Factors Present: Use antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS:
- Ciprofloxacin or levofloxacin 750mg, OR
- Aminoglycoside plus azithromycin, OR
- Aminoglycoside plus antipneumococcal fluoroquinolone 1
MRSA Suspected: Add vancomycin or linezolid 1
Penicillin Allergy: Respiratory fluoroquinolone plus aztreonam 1
Duration of Antibiotic Therapy
This represents a significant update from older guidelines:
Outpatients with Nonsevere CAP
Suggest less than 5 days (minimum 3 days) if clinical stability achieved 2, 3
- Clinical stability = afebrile 48-72 hours, no more than 1 CAP-associated sign of instability
- This is conditional and requires individualization
- Establish clear follow-up for symptom recurrence
Inpatients with Nonsevere CAP
Suggest less than 5 days (minimum 3 days) if clinical stability achieved 2, 3
- Over 50% of hospitalized patients may NOT be eligible for short courses
- Must resolve new oxygen requirements
- Contraindications include: severe chronic lung disease, bronchiectasis, necrotizing pneumonia, abscess, empyema
Severe CAP (ICU patients)
Strong recommendation for 5 or more days 2
- Higher risk of disseminated infection, necrotizing organisms, treatment failure
- Do NOT use shortened courses
Important exceptions requiring longer therapy:
- Pseudomonas, S. aureus, or resistant organisms
- Extrapulmonary complications (meningitis, endocarditis)
- Lack of response to initial therapy 1
Critical Pitfalls to Avoid
Do not use macrolide monotherapy in hospitalized patients - resistance rates make this inadequate 1
Do not delay first antibiotic dose - for ED admissions, give first dose while still in ED 1
Do not continue IV antibiotics unnecessarily - switch to oral when hemodynamically stable, improving clinically, able to ingest medications, and GI tract functioning 1
Do not use corticosteroids routinely - recent evidence conflicts; reserve for severe CAP with septic shock only 2, 4
Do not prescribe antibiotics for viral pneumonia in otherwise healthy patients - if positive viral testing and no comorbidities, antibiotics may not be needed unless imaging shows bacterial superinfection 4
Do not ignore local resistance patterns - empiric therapy must be based on local antibiogram data 1
Switching from IV to Oral Therapy
Switch when patient meets ALL criteria:
- Hemodynamically stable
- Clinically improving
- Able to ingest medications
- Normally functioning GI tract
- Can discharge once stable on oral therapy - no need for observation period 1